FY2028 EPS Forecast for Moderna Lowered by Analyst

Moderna, Inc. (NASDAQ:MRNA) – Research analysts at Brookline Capital Markets dropped their FY2028 earnings per share estimates for shares of Moderna in a research note issued to investors on Thursday, October 22nd. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings of ($0.54) per share for the year, down from their prior estimate of $0.62. Brookline Capital Markets currently has a “Buy” rating on the stock. The consensus estimate for Moderna’s current full-year earnings is ($6.11) per share.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter in the prior year, the company earned ($2.13) earnings per share. The business’s revenue was up 2.1% compared to the same quarter last year.

Other research analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a research report on Wednesday, September 9th. Evercore upped their price target on shares of Moderna from $50.00 to $80.00 in a research note on Thursday, October 8th. William Blair lowered shares of Moderna from an “outperform” rating to a “market perform” rating in a research report on Tuesday. Loop Capital set a $135.00 price objective on shares of Moderna in a research note on Wednesday, August 19th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $150.00 price objective (up from $60.00) on shares of Moderna in a research note on Wednesday, August 19th. Six equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $107.10.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $198.85 on Tuesday. The firm has a 50 day moving average of $173.86 and a 200 day moving average of $82.87. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $79.39 billion, a price-to-earnings ratio of -24.89 and a beta of 1.09. Moderna has a 12-month low of $22.28 and a 12-month high of $254.48.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MRNA. Merck & Co. Inc. acquired a new position in Moderna during the 2nd quarter valued at approximately $161,642,545. Louisiana State Employees Retirement System acquired a new position in Moderna during the 1st quarter valued at about $899,000. Bank of New York Mellon Corp bought a new stake in Moderna during the second quarter worth approximately $119,168,000. Contravisory Investment Management Inc. lifted its holdings in shares of Moderna by 1,387.6% in the second quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company’s stock valued at $1,696,000 after buying an additional 22,590 shares during the period. Finally, TD Waterhouse Canada Inc. lifted its holdings in Moderna by 2,042.6% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 72,591 shares of the company’s stock valued at $13,722,000 after acquiring an additional 69,203 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Insider Transactions at Moderna

In other news, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the transaction, the insider owned 74,129 shares in the company, valued at approximately $10,374,353.55. This represents a 4.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 39,145 shares of the stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $220.72, for a total value of $8,640,084.40. Following the sale, the president owned 1,636,565 shares in the company, valued at approximately $361,222,626.80. This trade represents a 2.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 197,251 shares of company stock valued at $33,875,904 over the last 90 days. 10.80% of the stock is currently owned by corporate insiders.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported that their individualized mRNA melanoma vaccine, intismeran, combined with KEYTRUDA, reduced the risk of recurrence or death by 42% versus KEYTRUDA alone. The trial also showed a 38% reduction in distant metastasis or death, and the results were accepted for publication in the New England Journal of Medicine. These findings support the program’s potential commercial value. Moderna Phase 3 melanoma vaccine results
• Neutral Sentiment: The vaccine’s Phase 3 success may eventually provide a significant new revenue stream for Moderna, which shares development costs and profits with Merck. However, the therapy has not yet generated sales, regulatory filings and launch timing remain uncertain, and manufacturing personalized doses at scale is untested. Moderna company information
• Negative Sentiment: Investors had anticipated results closer to the approximately 49% recurrence reduction seen in an earlier Phase 2b study. The Phase 3 benefit came in at the lower end of expectations, contributing to a sharp recent pullback despite the trial meeting its primary goal. Moderna’s rally may therefore have lost momentum as investors reassess whether the stock’s valuation already reflects much of the vaccine’s potential. Moderna cancer vaccine selloff
• Negative Sentiment: William Blair downgraded MRNA from “outperform” to “market perform,” signaling reduced expectations for further near-term upside. Separately, Brookline Capital Markets lowered its FY2028 EPS estimate from $0.62 to a loss of $0.54 per share, reinforcing concerns about the company’s path to profitability.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.